These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 15201230)
21. Virological and immunological responses of efavirenz-based HAART regimen initiated in HIV-infected patients at CD4 < 100 versus CD4 > or = 100 cells/mm3. Kiertiburanakul S; Sungkanuparph S; Rattanasiri S; Manosuthi W; Vibhagool A; Thakkinstian A J Med Assoc Thai; 2006 Sep; 89(9):1381-7. PubMed ID: 17100373 [TBL] [Abstract][Full Text] [Related]
22. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110 [TBL] [Abstract][Full Text] [Related]
23. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. Albrecht MA; Bosch RJ; Hammer SM; Liou SH; Kessler H; Para MF; Eron J; Valdez H; Dehlinger M; Katzenstein DA; N Engl J Med; 2001 Aug; 345(6):398-407. PubMed ID: 11496850 [TBL] [Abstract][Full Text] [Related]
24. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR; Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328 [TBL] [Abstract][Full Text] [Related]
25. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings. Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384 [TBL] [Abstract][Full Text] [Related]
26. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting. Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K; AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097 [TBL] [Abstract][Full Text] [Related]
27. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505 [TBL] [Abstract][Full Text] [Related]
28. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. Bartlett JA; Fath MJ; Demasi R; Hermes A; Quinn J; Mondou E; Rousseau F AIDS; 2006 Oct; 20(16):2051-64. PubMed ID: 17053351 [TBL] [Abstract][Full Text] [Related]
29. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens. Patel N; Abdelsayed S; Veve M; Miller CD Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025 [TBL] [Abstract][Full Text] [Related]
30. The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load. Bickel M; Rickerts V; Stephan C; Jacobi V; Rottmann C; Dauer B; Carlebach A; Thalhammer A; Miller V; Staszweski S HIV Med; 2005 May; 6(3):179-84. PubMed ID: 15876284 [TBL] [Abstract][Full Text] [Related]
31. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. Braithwaite RS; Kozal MJ; Chang CC; Roberts MS; Fultz SL; Goetz MB; Gibert C; Rodriguez-Barradas M; Mole L; Justice AC AIDS; 2007 Jul; 21(12):1579-89. PubMed ID: 17630553 [TBL] [Abstract][Full Text] [Related]
32. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort. Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307 [TBL] [Abstract][Full Text] [Related]
33. The use of efavirenz as a part of late rescue antiretroviral treatment. Manfredi R; Rizzo E; Calza L; Chiodo F HIV Clin Trials; 2001; 2(5):413-20. PubMed ID: 11673816 [TBL] [Abstract][Full Text] [Related]
34. Chemokine mRNA levels in mononucleated cells of HIV-infected patients before and after initiation of PI- versus NNRTI-containing HAART. Wasmuth JC; Nischalke HD; Jütte A; Fätkenheuer G; Salzberger B; Sauerbruch T; Spengler U; Rockstroh JK; Dumoulin FL Antiviral Res; 2004 Mar; 61(3):207-12. PubMed ID: 15168802 [TBL] [Abstract][Full Text] [Related]
35. [Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China]. Han XX; Zhang M; Cui WG; Liu BG; Wang Yn; Zhang ZN; Liu J; Geng WQ; Diao YY; Dai D; Jiang YJ; Shang H Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(11):760-4. PubMed ID: 15949383 [TBL] [Abstract][Full Text] [Related]
36. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program. Jaspan HB; Berrisford AE; Boulle AM Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556 [TBL] [Abstract][Full Text] [Related]
37. Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit. The AVANTI and INCAS Study Groups. AIDS; 2000 Jul; 14(10):1383-8. PubMed ID: 10930153 [TBL] [Abstract][Full Text] [Related]
38. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country. Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254 [TBL] [Abstract][Full Text] [Related]
39. Antiretroviral use in Italian children with perinatal HIV infection over a 14-year period. Chiappini E; Galli L; Tovo PA; Gabiano C; Lisi C; Giacomet V; Bernardi S; Esposito S; Rosso R; Giaquinto C; Badolato R; Guarino A; Maccabruni A; Masi M; Cellini M; Salvini F; Di Bari C; Dedoni M; Dodi I; de Martino M; Acta Paediatr; 2012 Jul; 101(7):e287-95. PubMed ID: 22452359 [TBL] [Abstract][Full Text] [Related]
40. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Puthanakit T; Oberdorfer A; Akarathum N; Kanjanavanit S; Wannarit P; Sirisanthana T; Sirisanthana V Clin Infect Dis; 2005 Jul; 41(1):100-7. PubMed ID: 15937769 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]